全文获取类型
收费全文 | 1023567篇 |
免费 | 72533篇 |
国内免费 | 2882篇 |
专业分类
耳鼻咽喉 | 14015篇 |
儿科学 | 31902篇 |
妇产科学 | 28311篇 |
基础医学 | 142578篇 |
口腔科学 | 27500篇 |
临床医学 | 87299篇 |
内科学 | 208519篇 |
皮肤病学 | 20667篇 |
神经病学 | 82447篇 |
特种医学 | 41384篇 |
外国民族医学 | 336篇 |
外科学 | 161724篇 |
综合类 | 20835篇 |
现状与发展 | 1篇 |
一般理论 | 414篇 |
预防医学 | 76149篇 |
眼科学 | 23067篇 |
药学 | 72689篇 |
2篇 | |
中国医学 | 1961篇 |
肿瘤学 | 57182篇 |
出版年
2021年 | 8224篇 |
2019年 | 8609篇 |
2018年 | 11779篇 |
2017年 | 9090篇 |
2016年 | 9744篇 |
2015年 | 11240篇 |
2014年 | 16040篇 |
2013年 | 24783篇 |
2012年 | 33800篇 |
2011年 | 35902篇 |
2010年 | 21389篇 |
2009年 | 20209篇 |
2008年 | 33848篇 |
2007年 | 35965篇 |
2006年 | 35782篇 |
2005年 | 35425篇 |
2004年 | 33975篇 |
2003年 | 32560篇 |
2002年 | 31962篇 |
2001年 | 42627篇 |
2000年 | 43602篇 |
1999年 | 37592篇 |
1998年 | 11481篇 |
1997年 | 10334篇 |
1996年 | 10207篇 |
1995年 | 9555篇 |
1994年 | 9004篇 |
1993年 | 8468篇 |
1992年 | 29008篇 |
1991年 | 27813篇 |
1990年 | 27148篇 |
1989年 | 26048篇 |
1988年 | 24237篇 |
1987年 | 23822篇 |
1986年 | 22932篇 |
1985年 | 21869篇 |
1984年 | 16643篇 |
1983年 | 14294篇 |
1982年 | 9124篇 |
1979年 | 15218篇 |
1978年 | 10855篇 |
1977年 | 9177篇 |
1976年 | 8657篇 |
1975年 | 9434篇 |
1974年 | 11160篇 |
1973年 | 10613篇 |
1972年 | 9972篇 |
1971年 | 9229篇 |
1970年 | 8846篇 |
1969年 | 8239篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
41.
Dermoscopic difficult lesions: an objective evaluation of reflectance confocal microscopy impact for accurate diagnosis
下载免费PDF全文
![点击此处可从《Journal of the European Academy of Dermatology and Venereology》网站下载免费的PDF全文](/ch/ext_images/free.gif)
42.
James Milligan Joseph Lee Matt Smith Lindsay Donaldson Peter Athanasopoulos Kent Bassett-Spiers 《The journal of spinal cord medicine》2020,43(2):223-233
Context: Persons with spinal cord injury (SCI) experience significant challenges when they access primary care and community services.Design: A provincial summit was held to direct research, education, and innovation for primary and community care for SCI.Setting: Toronto, Ontario, Canada.Participants: Key stakeholders (N?=?95) including persons with SCI and caregivers, clinicians from primary care, rehabilitation, and specialized care, researchers, advocacy groups, and policy makers.Methods: A one-day facilitated meeting that included guest speakers, panel discussions and small group discussions was held to generate potential solutions to current issues related to SCI care and to foster collaborative relationships to advance care for SCI. Perspectives on SCI management were shared by primary care, neurosurgery, rehabilitation, and members of the SCI communityOutcome Measures: Discussions were focused on five domains: knowledge translation and dissemination, application of best practices, communication, research, and patient service accessibility.Results: Summit participants identified issues and prioritized solutions to improve primary and community care including the creation of a network of key stakeholders to enable knowledge creation and dissemination; an online repository of SCI resources, integrated health records, and a clinical network for SCI care; development and implementation of strategies to improve care transitions across sectors; implementation of effective care models and improved access to services; and utilization of empowerment frameworks to support self-management.Conclusions: This summit identified priorities for further collaborative efforts to advance SCI primary and community care and will inform the development of a provincial SCI strategy aimed at improving the system of care for SCI. 相似文献
43.
44.
45.
46.
47.
48.
49.
E. Niclas Jonsson Rujia Xie Scott F. Marshall Rosalin H. Arends 《British journal of clinical pharmacology》2016,81(4):688-699
AimsThe aims were to 1) develop the pharmacokinetics model to describe and predict observed tanezumab concentrations over time, 2) test possible covariate parameter relationships that could influence clearance and distribution and 3) assess the impact of fixed dosing vs. a dosing regimen adjusted by body weight.MethodsIndividual concentration–time data were determined from 1608 patients in four phase 3 studies conducted to assess efficacy and safety of intravenous tanezumab. Patients received two or three intravenous doses (2.5, 5 or 10 mg) every 8 weeks. Blood samples for assessment of tanezumab PK were collected at baseline, 1 h post‐dose and at weeks 4, 8, 16 and 24 (or early termination) in all studies. Blood samples were collected at week 32 in two studies. Plasma samples were analyzed using a sensitive, specific, validated enzyme‐linked immunosorbent assay.ResultsA two compartment model with parallel linear and non‐linear elimination processes adequately described the data. Population estimates for clearance (CL), central volume (V
1), peripheral volume (V
2), inter‐compartmental clearance, maximum elimination capacity (VM) and concentration at half‐maximum elimination capacity were 0.135 l day–1, 2.71 l, 1.98 l, 0.371 l day–1, 8.03 μg day–1 and 27.7 ng ml–1, respectively. Inter‐individual variability (IIV) was included on CL, V
1, V
2 and VM. A mixture model accounted for the distribution of residual error. While gender, dose and creatinine clearance were significant covariates, only body weight as a covariate of CL, V
1 and V
2 significantly reduced IIV.ConclusionsThe small increase in variability associated with fixed dosing is consistent with other monoclonal antibodies and does not change risk : benefit. 相似文献
50.